Merck to Present at Sanford Bernstein 27th Strategic Decisions Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's president and chief executive officer, is scheduled to present at the Sanford Bernstein 27th Strategic Decisions Conference in New York on June 1 at 9:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html. An archive of the presentation will be available at the same location.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.



CONTACT:

Merck
Media:
Steven Campanini, 908-423-4291
or
Investors:
Carol Ferguson, 908-423-4465

KEYWORDS:   United States  North America  New Jersey  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.